Premium
Treatment of Amyotrophic Lateral Sclerosis with Thyrotropin‐Releasing Hormone (TRH)
Author(s) -
Yamane Kiyomi,
Osawa Mikio,
Kobayashi Itsuro,
Maruyama Shoichi
Publication year - 1986
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.1986.tb03140.x
Subject(s) - amyotrophic lateral sclerosis , thyrotropin releasing hormone , brainstem , medicine , neurotransmitter , spinal cord , pyramidal tracts , hormone , endocrinology , neuroscience , psychology , central nervous system , disease , anatomy
Despite the efforts of many workers, the cause and therapy has not been clarified. We carried out the therapeutic trial of thyrotropin releasing hormon (TRH) for amyotrophic lateral sclerosis (ALS) from January, 1979 to January, 1983. There were 16 subjects. The patients were given a low dose (0.5‐2 mg) of TRH intravenously or intramusculary. Mild to moderate improvement was found in 9 (56%) of 16 patients. TRH has been reported to have the activating effects on the pyramidal tract, brainstem motor nuclei, and motoneuron in the spinal cord as a neurotransmitter or neuromodulator. We thought such action of TRH to be useful to the therapy of ALS.